Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies
Andrea T Hooper, Selin Somersan-Karakaya, Shane E Mccarthy, Eleftherios Mylonakis, Shazia Ali, Jingning Mei, Rafia Bhore, Adnan Mahmood, Gregory P Geba, Paula Dakin, David M Weinreich, George D Yancopoulos, Gary A Herman, Jennifer D Hamilton
mBio, doi:10.1128/mbio.01699-22
We conducted a post hoc analysis in seropositive patients who were negative or borderline for functional neutralizing antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at baseline from a phase 1, 2, and 3 trial of casirivimab and imdevimab (CAS1IMD) treatment in hospitalized coronavirus disease 2019 (COVID-19) patients on low-flow or no supplemental oxygen prior to the emergence of Omicron-lineage variants. Patients were randomized to a single dose of 2.4 g CAS1IMD, 8.0 g CAS1IMD, or placebo. Patients seropositive for anti-SARS-CoV-2 antibodies at baseline were analyzed by their baseline neutralizing antibody status. At baseline, 20.6% (178/864) of seropositive patients were negative or borderline for neutralizing antibodies, indicating negative or very low functionally neutralizing anti-SARS-CoV-2 antibodies. CAS1IMD reduced viral load in patients who were negative or borderline for neutralizing antibodies versus placebo, but not in patients who were positive for neutralizing antibodies. In patients who were negative or borderline for neutralizing antibodies, we observed a trend in reduction of the proportion of patients who died or required mechanical ventilation, as well as in all-cause mortality, by day 29 with CAS1IMD versus placebo. The proportions of patients who died or required mechanical ventilation from days 1 to 29 were 19.1% in the placebo group and 10.9% in the CAS1IMD combined-dose group, and the proportions of patients who died (all-cause mortality) from days 1 to 29 were 16.2% in the placebo group and 9.1% in the CAS1IMD combined-dose group. In patients who were positive for neutralizing antibodies, no measurable harm or benefit was observed in either the proportion of patients who died or required mechanical ventilation or the proportion of patients who died (all-cause mortality). In hospitalized COVID-19 patients on low-flow or no supplemental oxygen, CAS1IMD reduced viral load, the risk of death or mechanical ventilation, and all-cause mortality in seropositive patients who were negative or borderline for neutralizing antibodies. IMPORTANCE The clinical benefit of CAS1IMD in hospitalized seronegative patients with COVID-19 has previously been demonstrated, although these studies observed no clinical benefit in seropositive patients. As the prevalence of SARS-CoV-2-seropositive individuals rises due to both vaccination and previous infection, it is important to understand whether there is a subset of hospitalized patients with COVID-19 with antibodies against SARS-CoV-2 who could benefit from anti-SARS-CoV-2 monoclonal antibody treatment. This post hoc analysis demonstrates that there is a subset of hospitalized seropositive patients with inadequate SARS-CoV-2-neutralizing antibodies (i.e., those who were
References
Andrews, Tessier, Stowe, Gower, Kirsebom et al., Duration of protection against mild and severe disease by Covid-19 vaccines, N Engl J Med,
doi:10.1056/NEJMoa2115481Bernal, Andrews, Gower, Gallagher, Simmons et al., Effectiveness of Covid-19 vaccines against the B.1 .617.2 (Delta) variant, N Engl J Med,
doi:10.1056/NEJMoa2108891Hansen, Baum, Pascal, Russo, Giordano et al., Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science,
doi:10.1126/science.abd0827Lundgren, Grund, Barkauskas, Holland, Gottlieb et al., Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels, Ann Intern Med,
doi:10.7326/M21-3507Montejano, Marcelo, Falces-Romero, Del Valle, Soto et al., Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV, AIDS,
doi:10.1097/QAD.0000000000003179Nordstrom, Ballin, Nordstrom, Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden, Lancet,
doi:10.1016/S0140-6736(22)00089-7O'brien, Forleo-Neto, Musser, Chan, Sarkar et al., Subcutaneous REGEN-COV antibody combination to prevent Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2109682Somersan-Karakaya, Mylonakis, Menon, Wells, Ali et al., Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19, J Infect Dis,
doi:10.1093/infdis/jiac320Stein, Oviedo-Orta, Kampman, Mcginniss, Betts et al., Compassionate use of REGEN-COV in patients with COVID-19 and immunodeficiency-associated antibody disorders, Clin Infect Dis,
doi:10.1093/cid/ciab1059Thomas, Moreira, Kitchin, Absalon, Gurtman et al., Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months, N Engl J Med,
doi:10.1056/NEJMoa2110345Vandergaast, Carey, Reiter, Lathrum, Lech et al., IMMUNO-COV v2.0: development and validation of a high-throughput clinical assay for measuring SARS-CoV-2-neutralizing antibody titers, NAb Status mBio
Vandergaast, Carey, Reiter, Lech, Gnanadurai et al., Development and validation of IMMUNO-COV: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2,
doi:10.1101/2020.05.26.117549Ward, Cooke, Whitaker, Redd, Eales et al., REACT-2 round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,
doi:10.1101/2021.02.26.21252512Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGEN-COV antibody combination and outcomes in outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2108163Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med,
doi:10.1056/NEJMoa2035002DOI record:
{
"DOI": "10.1128/mbio.01699-22",
"ISSN": [
"2150-7511"
],
"URL": "http://dx.doi.org/10.1128/mbio.01699-22",
"abstract": "<jats:p>The clinical benefit of CAS+IMD in hospitalized seronegative patients with COVID-19 has previously been demonstrated, although these studies observed no clinical benefit in seropositive patients. As the prevalence of SARS-CoV-2-seropositive individuals rises due to both vaccination and previous infection, it is important to understand whether there is a subset of hospitalized patients with COVID-19 with antibodies against SARS-CoV-2 who could benefit from anti-SARS-CoV-2 monoclonal antibody treatment.</jats:p>",
"alternative-id": [
"10.1128/mbio.01699-22"
],
"assertion": [
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Received",
"name": "received",
"order": 0,
"value": "2022-06-16"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Accepted",
"name": "accepted",
"order": 1,
"value": "2022-09-20"
},
{
"group": {
"label": "Publication History",
"name": "publication_history"
},
"label": "Published",
"name": "published",
"order": 2,
"value": "2022-10-18"
}
],
"author": [
{
"ORCID": "http://orcid.org/0000-0003-1131-1229",
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"authenticated-orcid": true,
"family": "Hooper",
"given": "Andrea T.",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Somersan-Karakaya",
"given": "Selin",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "McCarthy",
"given": "Shane E.",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-4624-0777",
"affiliation": [
{
"name": "Brown University, Providence, Rhode Island, USA"
}
],
"authenticated-orcid": true,
"family": "Mylonakis",
"given": "Eleftherios",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Ali",
"given": "Shazia",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Mei",
"given": "Jingning",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Bhore",
"given": "Rafia",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Mahmood",
"given": "Adnan",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Geba",
"given": "Gregory P.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Dakin",
"given": "Paula",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Weinreich",
"given": "David M.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Yancopoulos",
"given": "George D.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Herman",
"given": "Gary A.",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA"
}
],
"family": "Hamilton",
"given": "Jennifer D.",
"sequence": "additional"
}
],
"container-title": "mBio",
"container-title-short": "mBio",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"journals.asm.org"
]
},
"created": {
"date-parts": [
[
2022,
10,
18
]
],
"date-time": "2022-10-18T13:15:16Z",
"timestamp": 1666098916000
},
"deposited": {
"date-parts": [
[
2022,
12,
20
]
],
"date-time": "2022-12-20T14:16:36Z",
"timestamp": 1671545796000
},
"editor": [
{
"affiliation": [],
"family": "Miller",
"given": "Matthew S.",
"sequence": "additional"
}
],
"indexed": {
"date-parts": [
[
2024,
5,
1
]
],
"date-time": "2024-05-01T00:54:43Z",
"timestamp": 1714524883376
},
"is-referenced-by-count": 3,
"issue": "6",
"issued": {
"date-parts": [
[
2022,
12,
20
]
]
},
"journal-issue": {
"issue": "6",
"published-print": {
"date-parts": [
[
2022,
12,
20
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
12,
20
]
],
"date-time": "2022-12-20T00:00:00Z",
"timestamp": 1671494400000
}
},
{
"URL": "https://journals.asm.org/non-commercial-tdm-license",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
12,
20
]
],
"date-time": "2022-12-20T00:00:00Z",
"timestamp": 1671494400000
}
}
],
"link": [
{
"URL": "https://journals.asm.org/doi/pdf/10.1128/mbio.01699-22",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://journals.asm.org/doi/pdf/10.1128/mbio.01699-22",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "235",
"original-title": [],
"prefix": "10.1128",
"published": {
"date-parts": [
[
2022,
12,
20
]
]
},
"published-print": {
"date-parts": [
[
2022,
12,
20
]
]
},
"publisher": "American Society for Microbiology",
"reference": [
{
"DOI": "10.1056/NEJMoa2115481",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_2_2"
},
{
"DOI": "10.1056/NEJMoa2108891",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_3_2"
},
{
"DOI": "10.1056/NEJMoa2110345",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_4_2"
},
{
"DOI": "10.1101/2021.02.26.21252512",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_5_2"
},
{
"DOI": "10.1101/2022.03.21.22272672",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_6_2"
},
{
"DOI": "10.1093/cid/ciab1059",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_7_2"
},
{
"DOI": "10.1097/QAD.0000000000003179",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_8_2"
},
{
"DOI": "10.1126/science.abd0827",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_9_2"
},
{
"DOI": "10.1056/NEJMoa2108163",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_10_2"
},
{
"DOI": "10.1056/NEJMoa2109682",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_11_2"
},
{
"DOI": "10.1016/S0140-6736(22)00163-5",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_12_2"
},
{
"DOI": "10.1093/infdis/jiac320",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_13_2"
},
{
"key": "e_1_3_2_14_2",
"unstructured": "Centers for Disease Control and Prevention. Nationwide COVID-19 infection- and vaccination-induced antibody seroprevalence (blood donations). https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence. Accessed 22 March 2022."
},
{
"key": "e_1_3_2_15_2",
"unstructured": "Regeneron Pharmaceuticals Inc. 2021. Regeneron’s next generation monoclonal antibodies are active against all known variants of concern including both Omicron and Delta. https://investor.regeneron.com/static-files/4aed42a1-3d26-48af-bd01-3f0c92938c11. Accessed 10 March 2022."
},
{
"key": "e_1_3_2_16_2",
"unstructured": "U.S. Food and Drug Administration. 2021. Fact sheet for health care providers. Emergency use authorization (EUA) of REGEN-COV (casirivimab and imdevimab). https://www.fda.gov/media/145611/download. Accessed 24 June 2021."
},
{
"DOI": "10.1101/2020.05.26.117549",
"doi-asserted-by": "crossref",
"key": "e_1_3_2_17_2",
"unstructured": "Vandergaast R Carey T Reiter S Lech P Gnanadurai C Tesfay M Buehler J Suksanpaisan L Naik S Brunton B Recker J Haselton M Ziegler C Roesler A Mills JR Theel E Weaver SC Rafael G Roforth MM Jerde C Tran S Diaz RM Bexon A Baum A Kyratsous CA Peng KW Russell SJ. 2020. Development and validation of IMMUNO-COV: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2. bioRxiv doi:10.1101/2020.05.26.117549."
},
{
"DOI": "10.7326/M21-3507",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_18_2"
},
{
"key": "e_1_3_2_19_2",
"unstructured": "U.S. Food and Drug Administration. 2022. Emergency use authorization 091. https://www.fda.gov/media/145610/download. Accessed 10 February 2022."
},
{
"DOI": "10.1016/S0140-6736(22)00089-7",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_20_2"
},
{
"DOI": "10.1056/NEJMoa2035002",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_21_2"
},
{
"DOI": "10.1128/mSphere.00170-21",
"doi-asserted-by": "publisher",
"key": "e_1_3_2_22_2"
}
],
"reference-count": 21,
"references-count": 21,
"relation": {
"has-preprint": [
{
"asserted-by": "object",
"id": "10.1101/2022.06.14.22276389",
"id-type": "doi"
}
]
},
"resource": {
"primary": {
"URL": "https://journals.asm.org/doi/10.1128/mbio.01699-22"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1128/asmj-crossmark-policy-page",
"volume": "13"
}
